Switching from Glargine to Degludec is not associated with an overt change in glucose control in a cohort of patients with type 1 diabetes: a CGM analysis
- 485 Downloads
After DCCT, intensive multiple daily insulin injections protocol became the standard therapy for patients with T1DM intended to maintain a lower HbA1c without hypoglycemia and thus to decrease the risk of microvascular complications. Design and production of new basal insulin analogs with lower risk of hypoglycemia was the next challenge. The switch from NPH to the basal insulin analog Glargine represented a major clinical advantage allowing to obtain a better and safer glucose control. Degludec is a new basal insulin analog with longer half-life and lower variability than Glargine . Despite these differences, clinical trials comparing Glargine and Degludec in patients with T1DM and T2DM have failed to show a clear clinical advantage of Degludec in both efficacy and safety. A statistically significant lower number of hypoglycemic events, associated with Degludec versus Glargine, have been shown only in patients at high risk of hypoglycemia and intensively treated...
KeywordsDegludec Glargine Continuous glucose monitoring Hypoglycemia
Continuous glucose monitoring
Neutral protamine hagedorn
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Area under curve
Continuous overlapping net glycemic action
Blood glucose rate
Low Blood Glucose Index
High Blood Glucose Index
Mean amplitude glycemic excursion
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the 1975 Declaration of Helsinki, as revised in 2008.
Informed consent was obtained from all individual participants included in the study.
- 2.Siegmund T, Tentolouris N, Knudsen ST et al (2017) A European multicentre retrospective non interventional study (EU-TREAT) of the effectiveness of insulin Degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. https://doi.org/10.1111/dom.13149 PubMedPubMedCentralCrossRefGoogle Scholar